bevacizumab,trifluridine tipiracil
taiho pharma,roche,otsuka
[]
. #gi23: data from the phase 3 sunlight study, presented by vhio s director point to trifluridine/tipiracil plus bevacizumab as practice-changing care for 3rd line treatment of refractory metastatic colorectal cancer. 
Leading translational research to accelerate & advance personalized and targeted therapies against cancer. 
@iCERCA centre